JPRN-jRCT2080223677未知3 期
A Phase III, multi-center, randomized, double-blind, non-inferiority study of Solithromycin versus Cefcapene pivoxil hydrochloride hydrate in patients with sinusitis
Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)0 个研究点开始时间: 2017年10月13日最近更新:
试验速览
- 阶段
- 3 期
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •1.Age: 20 years of age and older (at the time of obtaining informed consents)
- •2.Gender : Both
- •3.Inpatient/Outpatient status: Outpatient
- •4.Signed the informed consent form by patients
- •5.Sinusitis with clear infection symptoms
排除标准
- •1.Having improvement of clinical symptoms due to target disease by other systemic antibiotics
- •2.Having a history of allergy to macrolide, penicillin or cephem antibiotics
研究者
相似试验
进行中（未招募）
1 期
Placebo-controlled study of the safety and efficacy of osilodrostat in patients with Cushing's DiseaseCushing's diseaseMedDRA version: 20.0Level: LLTClassification code 10011651Term: Cushing's diseaseSystem Organ Class: 100000004860EUCTR2014-004092-23-PTovartis Pharma Services AG74
未知
3 期
A Phase III study of Solithromycin in patients with community-acquired pneumoniaCommunity-acquired pneumoniaJPRN-jRCT2080223384Toyama Chemical Co., Ltd.(Current FUJIFILM Toyama Chemical Co., Ltd.)
进行中（未招募）
不适用
A Phase III, multi-center, randomized, double-blind comparator study to evaluate the efficacy and safety of 50 mg and 100 mg of TAK-013 tablets administered twice daily versus 3.75mg of Leuprolide administered monthly for 24 weeks in subjects with symptomatic endometriosis.MedDRA version: 7Level: LLTClassification code 10014778EndometriosisEUCTR2004-001720-21-GBTakeda Europe R&D Centre Ltd200
进行中（未招募）
1 期
Placebo-controlled study of the safety and efficacy of osilodrostat in patients with Cushing's DiseaseCushing's diseaseMedDRA version: 19.0Level: LLTClassification code 10011651Term: Cushing's diseaseSystem Organ Class: 100000004860EUCTR2014-004092-23-GRovartis Pharma Services AG69
进行中（未招募）
1 期
Placebo-controlled study of the safety and efficacy of osilodrostat in patients with Cushing's DiseaseCushing's diseaseMedDRA version: 20.0Level: LLTClassification code 10011651Term: Cushing's diseaseSystem Organ Class: 100000004860EUCTR2014-004092-23-PLovartis Pharma Services AG74